WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central review–assessed PFS as the primary end point. Sunvozertinib improved PFS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results